from schizoidman@lemmy.zip to world@lemmy.world on 27 Jan 01:57
https://lemmy.zip/post/57844486
Investors in western biotechs face the prospect of lower valuations as Chinese start-ups attract growing investment from global drugmakers looking to replenish their pipelines.
Chinese companies account for more than half of new ADC drugs in early clinical trials, according to consultancy McKinsey. They are also making strides in developing next-generation Car-T treatments for autoimmune diseases, and small interfering RNA (siRNA) therapies. These can temporarily turn off harmful genes.
In the past year, more than $85bn of licensing deals involving Chinese companies have been signed across more than 100 transactions. Most relate to early-stage drugs where foreign companies take on the rights for further trials and commercialisation outside the country.
#world
threaded - newest